Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MSLP, IDIX, INVE, IDRA - Weekend Stock Alert For Crwepicks.com

MusclePharm® Corporation (OTCBB:MSLP)

MusclePharm’s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside™. Headquartered in Denver, Colorado, the company is a fast-growing developer and manufacturer of safe, scientifically approved nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MusclePharm product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists. In addition, the products have been field-tested by more than 100 elite professional athletes from the NFL, MMA, MLB and elsewhere. To date, the company has developed eight products: ASSAULT®, BATTLE FUEL®, BULLET PROOF®, COMBAT POWDER®, RECON®, SHRED MATRIX®, and MUSCLEGEL®. Two additional products are due in stores in 2010. MusclePharm products offer up to twice as much of the active ingredients per serving as competing products and incorporate a proprietary mix of ingredients not available elsewhere, such as Suma root– the “Russian Secret.” Suma is a natural, performance-boosting, strength-and muscle-building herbal derivative that has been used for years by top Russian athletes.

If you go back to 1984, Nike (NYSE:NKE) was trading as low as $0.41 per share. It was NKE’s association with Michael Jordan that propelled NKE into becoming a household name. NKE today trades for $73.64 a gain of 17,860% over the past 26 years. Anderson Silva is the Michael Jordan of MMA! MusclePharm is quickly becoming a household name in MMA circles. I doubt MSLP will ever become as big as NKE, but I certainly believe MSLP has astronomical upside potential at its current price of $0.75!

MusclePharm® Corporation, one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, reported today that MusclePharm athlete and NFL star Joey Porter will wear MusclePharm’s new clothing line during a 17-episode weekly series spanning the 2010 NFL season on NFL Network.

The new MusclePharm-branded hats and shirts will be unveiled to the retail market in the coming weeks and Porter’s notoriety in the world’s most popular sport presents an ideal platform to create exposure for the product line.

Consistently recognized as one of the most recognizable faces in the NFL thanks to his outgoing nature, Porter will be wearing MusclePharm apparel in all 17 episodes of a weekly NFL Network series that focuses on the upcoming NFL season.

The Arizona Cardinals and Super Bowl-winning linebacker is a 4-time Pro Bowler and was voted one of the top defensive players of the last decade. Porter has been an important MusclePharm spokesman due to his relentless playing style, tireless work ethic and outspoken personality, making this project a perfect way to reveal the new MusclePharm-branded apparel.

“At MusclePharm, we find creative ways to make our brand stand out to multiple audiences and in multiple formats to reach all consumers,” said Cory Gregory, MusclePharm’s President. “We currently have focused on brand awareness in marketing in the UFC, NFL, MLB and in action sports markets. We believe we are a company that crosses over to multiple demographics and helps all of these athletes in these different sports, while also appealing to the normal, everyday athlete.”

MusclePharm products are currently available in 1,200 of the top General Nutrition Centers (NYSE:GNC) in the United States, as well as Vitamin Shop. MusclePharm’s award-winning products — Assault®, Battle Fuel®, Bullet Proof®, Combat Powder®, Recon® and Shred Matrix®—are also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.

 

 

Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, recently reported that three abstracts have been accepted for presentation at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 29-November 2, 2010 in Boston, Massachusetts).

The abstracts being presented are on three of the company’s hepatitis C clinical programs: IDX184, IDX320 and IDX375.

 

Identive Group, Inc. (Nasdaq: INVE) a provider of products, services and solutions for the security, identification and RFID industries, reported recently the expansion of its signature Multicard brand into the United States.

Following its acquisition by Identive in April of this year, RockWest Technology Group announced that it will adopt the name of Multicard, joining with sister companies in Europe and Australia.

 

Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) recently announced that data related to IMO-2125, its novel immune modulator for the treatment of chronic hepatitis C virus (HCV) infection, will be presented at the 61st Annual Meeting of the American Association of the Study of Liver Diseases in Boston, Massachusetts October 29 – November 2, 2010.

*******************************************
Sign-Up For Free Stock Alerts At crwepicks.com/signup
*******************************************

 


THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. The fee may be in cash, in free trading stock, in restricted stock, or in any combination thereof. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP).